N/A N=100 Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality
Myopia-Night Blindness
Primary: Night Myopia — -0.30; -0.32 D
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Blue Blockers at Night and Insomnia Symptoms
Insomnia · Sleep
Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale
Phase 2 N=24 Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Decrease in Night Vision · Disturbance; Vision, Loss
Primary: Contrast Sensitivity — 0.6; 0.8; 0.9; 0.7 Patches
N/A N=21 Toileting at Night in Older Adults: Light to Maximize Balance, Minimize Insomnia
Falls · Balance · Insomnia
Primary: Change in Balance — 6.66; 5.34; 5.62; 5.78 %CV
Phase 3 N=144 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Dim Light Vision Disturbances
Primary: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye — 9; 2 Participants
N/A N=33 Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Non-visual Photoreception
Primary: Melatonin Suppression — 71.4; 70.1; 54.3; 32.5 Percentage suppression — p=0.73
Phase 3 N=43 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
Presbyopia
Primary: Overall Composite Driving Z Score Approximately 1 Hour After Study Intervention Instillation — 0.118; -0.121 Z-score — p=0.0006
N/A N=36 Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment
Mild Cognitive Impairment · Alzheimer Disease
Primary: Melatonin Levels — 0.89; 0.84; 0.9; 0.68 pg/mL
N/A N=80 Effects of Blue-light Blocking Lens on Visual Functions
Effects of Blue-light Blocking Lens on Visual Functions
Primary: Contrast Sensitivity as Assessed by Mars Contrast Sensitivity Chart — 1.866; 1.861; 1.856; 1.818 log contrast sensitivity score
Early Phase 1 N=8 Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
AMD
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
N/A N=21 Visual Activity Evoked by Infrared in Humans After Dark Adaptation
Age Related Macular Degeneration · Retinitis Pigmentosa · Congenital Stationary Night Blindness
Primary: Visual Perception to Infrared: Mean Minimal Intensity (uW) at Which Participants Could See IR Between 900 - 1400 nm. — 0.671770454; 0.809204; 0.205456012; 0.222247 uW…
Phase 2 N=24 Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance
Visual Performance
Primary: Overall Nighttime Driving Score — -0.308; -0.375; -0.430 Z-Score
N/A N=109 Macular Pigment and Glare Disability
Vision, Entoptic
Primary: Macular Pigment Optical Density — 0.54; 0.42 optical density — p=0.01
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
N/A N=68 Functional Vision With ACRYSOF® IQ IOLs Blue Light Filtration
Cataract
Primary: Change in Braking Reaction Time From No-glare to Glare — 0.07; 0.15 seconds
N/A N=58 Blue Light Intraocular Lenses (IOLs) and Photostress
Cataract
Primary: Photostress Recovery Time in Seconds. — 36; 41.46; 24.88 seconds
N/A N=20 Wearable Dark-adaptometer in Normal Adult Healthy Volunteers
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
N/A N=12 Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
N/A N=154 Effect of Blue Light Filtration on Visual Performance
Cataract
Primary: Photostress Recovery Time — 5.66; 6.94 seconds
Phase 2 N=31 Side Effects of Atropine (SEA) Study
Myopia
Primary: Diameter of the Pupil Measured With a Neuroptix Pupillometer — 4.9; 5.1; 5.9; 5.9 millimeters — p=0.002
Phase 2 N=12 Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
Ocular Hypertension · Open Angle Glaucoma
Primary: Change in Intraocular Pressure (IOP) Over Nocturnal Time Period — 22.84; 23.56; 19.38; 23.19 mmHg
N/A N=15 Circadian Macular Volume Changes in the Choroid
Choroid Physiology
Primary: Macular Choroidal Volume — 10.33 mm^3
N/A N=34 Glasses for Adolescent Delayed Sleep-Wake Phase Disorder
Delayed Sleep-Wake Phase Disorder
Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours
N/A N=22 Blue Wavelength Light-blocking Glasses in ADHD-Insomnia
Attention Deficit Hyperactivity Disorder · Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Primary: Pittsburgh Sleep Quality Index (PSQI) at 2 Weeks After Baseline — 4.54 units on a scale
Phase 3 N=241 Improving Function in Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47
N/A N=46 Individually Tailored Lighting System to Improve Sleep in Older Adults
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
Phase 2 N=78 DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa · X-linked Genetic Diseases
Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30
N/A N=15 Morning Light Treatment at Home to Reduce PTSD Symptoms
PTSD
Primary: Change in PTSD Checklist for DSM-5 (PCL-5) Scores Over 4 Weeks of Treatment — 15.11; 2.50 units on a scale
N/A N=161 How Has Glaucoma Affected Your Quality of Life?
Glaucoma · Quality of Life
Primary: Quality of Life With NEI VFQ-25 — 82.9; 82.7; 82.8; 83.0 units on a scale
N/A N=60 The Effects of Contact Lenses With Experimental Dye on Visual Function
Ametropia
Primary: Two-Point Light Spread Function — 5.36; 6.71; 6.47; 7.48 mm